A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

NCT01195974 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: YASMIN
DRUG: GSK2248761
OTHER: Placebo

Sponsor

ViiV Healthcare

Collaborators

[object Object]